According to the findings of O'Farrell et al., there should be a strong indication for ADT in males with prostate cancer such that the benefits outweigh the risks; this is especially important in males with a recent history of CVD [28]. When compared to GnRH agonists, Teoh et al. claim that surgical castration is linked to a greater risk of cardiovascular thrombotic events. This evidence concerns the gene GNRH1 and Familial prostate cancer.